This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Bailey, C. J Articles by Krentz, A. J Search for Related Content Social Bookmarking                         What's this?

Nice timing for glitazones

Diabetes Group, Aston University, Birmingham, UK, c.j.bailey{at}aston.ac.uk

Caroline Day

Diabetes Group, Aston University, Birmingham, UK

Andrew J Krentz

Southampton General Hospital, Tremona Road, Southampton, SO16 6YD, UK

The National Institute for Clinical Excellence (NICE) recently revised its guidance on the use of thiazolidinediones (TZDs). Days later, the European Agency for the Evaluation of Medicinal Products (EMEA) announced licence changes for TZDs that supersede the NICE guidance. The EMEA has approved TZDs for monotherapy if metformin is contraindicated or not tolerated. This article summarises the latest changes surrounding the use of TZDs in the UK.

Key Words: thiazolidinediones • pioglitazone • rosiglitazone • NICE • EMEA.

References

• Bailey CJ, Day C. Thiazolidinediones today. Br J Diabetes Vasc Dis 2001; 1:7-13.[Abstract/Free Full Text]
• Day C. Thiazolidinediones: a new class of antidiabetic drugs. Diabetic Med 1999;16:179-92.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Bailey CJ, Day C., Krentz AJ Glitazone guidelines: clarity or confusion? Prescriber 2001;66-9.
• National Institute for Clinical Excellence (NICE). Technology appraisal guidance No. 63, 2003.
• National Institute for Clinical Excellence (NICE). Technology appraisal guidance No. 9, 2000.
• National Institute for Clinical Excellence (NICE). Technology appraisal guidance No. 21, 2001.
• European Agency for the Evaluation of Medicinal Products (EMEA). www.emea.eu.int
• Food and Drug Administration (FDA). www.fda.gov
• Barnett D. Personal communication to AJK, 2003.

The British Journal of Diabetes & Vascular Disease, Vol. 3, No. 5, 366-367 (2003)
DOI: 10.1177/14746514030030051001


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Bailey, C. J Articles by Krentz, A. J Search for Related Content Social Bookmarking                         What's this?